Several studies indicate that the development of chronic lymphocytic leukemia (CLL) may be influenced by antigen recognition through the clonotypic B-cell receptors (BCRs). However, it is still unclear whether antigen involvement is restricted to the malignant transformation phase or whether the putative antigen(s) may continuously trigger the CLL clone and affect not only the progenitor cell but also the leukemic cells themselves. To address this issue, we conducted a large-scale subcloning study of rearranged immunoglobulin heavy variable (IGHV) genes of diverse mutational status from 71 CLL cases (total: 1496 subcloned sequences), belonging to both the common IgM/IgD variant and the rare IgG-positive variant. Although most cases showed no or low levels of intraclonal diversification (ID), we report intense ID in the IGHV genes of selected cases, especially a subgroup of 13 IgG-switched cases expressing stereotyped, mutated IGHV4-34 rearrangements (subset #4). We demonstrate that the ID evident in subset #4 cases cannot be attributed to IGHV4-34 usage, IGHV gene-mutated status, class-switch recombination or BCR stereotypy in general, rather it represents a unique phenomenon strongly correlated with the distinctive BCR of subset #4. In such cases, the observed ID patterns may imply a stereotyped response to an active, ongoing interaction with antigen(s).
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ABSTRACT
Several studies indicate that the development of chronic lymphocytic leukemia (CLL) may be influenced by antigen recognition through the clonotypic B-cell receptors (BCRs). However, it is still unclear whether antigen involvement is restricted to the malignant transformation phase or whether the putative antigen(s) may continuously trigger the CLL clone and affect not only the progenitor cell but also the leukemic cells themselves. To address this issue, we conducted a large-scale subcloning study of rearranged immunoglobulin heavy variable (IGHV) genes of diverse mutational status from 71 CLL cases (total: 1496 subcloned sequences), belonging to both the common IgM/IgD variant and the rare IgG-positive variant. Although most cases showed no or low levels of intraclonal diversification (ID), we report intense ID in the IGHV genes of selected cases, especially a subgroup of 13 IgG-switched cases expressing stereotyped, mutated IGHV4-34 rearrangements (subset #4). We demonstrate that the ID evident in subset #4 cases cannot be attributed to IGHV4-34 usage, IGHV gene-mutated status, class-switch recombination or BCR stereotypy in general, rather it represents a unique phenomenon strongly correlated with the distinctive BCR of subset #4. In such cases, the observed ID patterns may imply a stereotyped response to an active, ongoing interaction with antigen(s).
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INTRODUCTION
Over the last decade, immunophenotypical and gene expression profiling studies have provided conclusive evidence that chronic lymphocytic leukemia (CLL) malignant B cells are antigen-experienced. [1] [2] [3] A strong sequence-based argumentation supporting the role of antigen in CLL was the finding that somatic hypermutations (SHM) are present in the immunoglobulin heavy variable (IGHV) genes expressed by the leukemic B cells in more than 50% of CLL cases. [4] [5] The presence or absence of mutations was shown to have important clinical implications and is now widely used to segregate CLL cases into two clinical entities displaying significantly different outcomes. [6] [7] Further evidence for the role of antigen in leukemogenesis is the remarkably restricted IGHV gene repertoire of CLL, with just a handful of genes predominating (e.g. IGHV1-69, IGHV4-34, IGHV3-7, IGHV3-23, IGHV3-21). 5, [8] [9] From a sequence perspective, however, the most striking argument for the active role of antigen in CLL is the existence of subsets of geographically distant and unrelated cases with quasiidentical, "stereotyped" B cell receptors (BCRs). [10] [11] [12] [13] [14] [15] [16] [17] [18] Interestingly, cases expressing certain stereotyped BCRs may also share other biological and clinical features. For instance, the IGHV3-21/IGLV3-21 subset (known as subset #2 17 ) has been associated with a poor prognosis irrespective of IGHV gene mutational status. [16] [17] 19 In contrast, the IGHV4-34/IGKV2-30 subset (known as subset #4 17 ) appears to be associated with an indolent course of the disease. 17 Furthermore, cases belonging to this subset are relatively young 17 and uniformly express IgG-switched IGs. [17] [18] We recently demonstrated the existence of more than 100 different subsets with stereotyped heavy-chain complementarity-determining region 3 (HCDR3) sequences in a series of 1939 patients with CLL. 18 A comprehensive analysis of SHM in the same series revealed "CLL-biased" SHM patterns typified by recurrent hypermutations throughout the entire IGHV region in subsets of cases with stereotyped HCDR3s, in particular those expressing stereotyped IGHV3-21/IGLV3-21 IGs (subset #2) and IGHV4-34/IGKV2-30 IGs (subset #4).
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Whilst the study of IG genes in CLL has strongly implicated an antigen-driven model of CLL development, an as yet unanswered question concerns the B cell developmental stage when leukemic transformation occurred. [20] [21] Furthermore, it is still unclear whether antigen involvement is restricted to the malignant transformation phase or whether the putative antigen(s) may continuously trigger the CLL clone and affect not only the progenitor cell but also the leukemic cells themselves. [20] [21] For personal use only. on . by guest www.bloodjournal.org From
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Evidence from several other types of B cell lymphoproliferative disorders suggests that valuable insight into these issues may be gleaned from the study of intraclonal diversification (ID) within IG genes through ongoing mutational activity. Evidence of ID pointing to ongoing SHM has been observed in several types of B cell malignancies, [22] [23] [24] [25] [26] [27] [28] thereby indicating that the neoplastic cells interact continuously with their cognate antigen(s). On the contrary, multiple myeloma is conspicuous for a complete lack of ID within IG genes, supporting the notion that malignant transformation likely occurs at a post-germinal center stage of B cell development. [29] [30] The available data on ID within IG genes in CLL are limited and conflicting. Several studies demonstrate some level of ID (ranging from limited to pronounced) leading to clonal evolution, [31] [32] [33] [34] [35] [36] with only one study reporting a complete lack of ID. 37 We conducted the present study in order to address these discrepancies and systematically explore the issue as to whether CLL cells continue to acquire hypermutations following leukemic transformation. To this end, we followed a very stringent methodology and conducted a comprehensive analysis of ID in IGHV genes of diverse mutational status from 71 patients with CLL, belonging to the common IgM/IgD variant and the rare IgG-positive variant. Although the majority of cases showed no or low levels of ID, an intense and functionally driven ID process was evident in selected cases, especially those belonging to subset #4, who express highly distinctive, stereotyped IGHV4-34/IGKV2-30 BCRs [17] [18] . In such cases, the observed ID patterns among sets of subcloned IG sequences attest to the very precise targeting of the SHM process and may be considered as evidence for a "stereotyped response" to an active, ongoing interaction with antigen(s).
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PATIENTS AND METHODS
Patient Group
Seventy-one patients with CLL from collaborating institutions in Scandinavia and Greece were included in the study. The main criteria for case selection were IGHV gene usage and mutational status. Thus, our study is intentionally biased for cases utilizing the IGHV3-21 and IGHV4-34 genes (25/71 and 28/71 cases, respectively).
All cases were immunophenotyped as described previously 10, 15, [17] [18] 
Sequence data analysis
The sequences obtained from subcloning were analyzed with the IMGT V-QUEST 40 and ClustalW/EMBL 41 tools. In order to avoid misidentification of mutations when HFR1 consensus primers were used in the amplification reactions, nucleotide changes in the obtained sequences were evaluated from codon 24 in IMGT-HFR1 to the end of HCDR3. For the subgroup of cases amplified using leader primers and a constant region primer, the entire V region was evaluated (from IMGT HFR1 codon 1 down to the end of HFR4). The following information was extracted: (i) IGHV gene usage, percentage of identity to germline, and HCDR3 length; (ii) somatic hypermutation characteristics: each nucleotide mutation in every sequence was recorded, as was the change or preservation of the corresponding amino acid (AA), identified as replacement (R) or silent (S), respectively. AA changes were characterized as 'conservative' or 'non-conservative' following standardized biochemical criteria, as previously described. 42 In order to account for the fact that a mutation is more likely to occur in a HFR than a HCDR simply due to its greater length, each mutation was 'weighted', or normalized, as recently reported by our 
43-44
Definitions
Intraclonal heterogeneity in sets of subcloned sequences obtained from the same sample was assessed by examination of the sequence variation in the V domain. All "non-ubiquitous" sequence changes from the germline were evaluated and further characterized as follows: (i) unconfirmed mutation (UCM) -a mutation observed in only one subcloned sequence from the same specimen ("unique"); (ii) confirmed mutation (CM) -a mutation observed more than once among subcloned sequences from the same specimen ("partially shared"). Amino acid changes due to UCMs or CMs are designated by the abbreviations UAA or CAA, respectively.
In order to compare mutation counts between the different rearrangements included in the analysis, mutations were normalized to both the nucleotide length and the number of subcloned sequences for each rearrangement. Thus, the normalized mutation frequencies (NMF) were calculated according to the following formula:
∑ (CM+UCM)/number of subcloned sequences*sequence length -for instance, if 9 mutations (confirmed and/or unconfirmed) were identified in a set of 20 subcloned
For personal use only. on . by guest www.bloodjournal.org From sequences of a certain rearrangement over a region of 300 nucleotides, the NMF for this rearrangement would be: 9/(20*300)=1.5x10 -3 .
Evolutionary history of sets of subcloned sequences
The evolutionary history of the sets of subcloned sequences was inferred using the Maximum Parsimony (MP) method. 45 The MP trees were obtained using the CloseNeighbor-Interchange algorithm with search level 2 in which the initial trees were obtained with the random addition of sequences (10 replicates) 45 . Branch lengths were calculated using the average pathway method 45 and are in the units of the number of changes over the whole sequence. They are shown next to the branches.
The tree is drawn to scale. All positions containing gaps and missing data were eliminated from the dataset (Complete Deletion option). Phylogenetic analyses were conducted in MEGA4. Forty-six of 71 cases expressed stereotyped BCRs and were assigned to eleven different subsets, as previously described (Supplemental Table 1 [17] [18] . Notably, subset #4 and #16 cases were uniformly mutated, whereas subset #2 cases exhibited significant heterogeneity with regard to mutational load (Supplemental Table 1 ); finally, all subset #8 cases had 100% germline identity. The heavy chain isotype was the same among members of a subset (for cases with available data). All subsets expressed IgMD, except for subsets #4 (IGHV4-34 gene), #8 (IGHV4-39 gene) and #16 (IGHV4-34 gene), which included IgG-expressing cases, as previously reported 13, [17] [18] . Table 2 ).
Intraclonal diversification analysis at the nucleotide level
Based on direct sequencing analysis, 23/28 cases (82%) carrying CMs belonged to the "mutated" category (<98% germline identity). Table 2 ). Interestingly, the high number of CMs (and UCMs) observed in several subset #4 cases (P0103, P1422, P2451, P2920, P3551, Swe56) could be attributed to the existence of distinct "clusters" of subcloned sequences with For
Intraclonal diversification of IGHV-D-J rearrangements at the amino acid level
A total of 273 novel amino acid (AA) changes and two single-AA deletions were identified in 47/71 evaluated cases (66.2%). Following definitions presented in the Patients and Methods section, 134/273 AA changes (49%) were considered as unconfirmed (UAA), whereas the remainder (139/273; 51%) were detected in at least two subcloned sequences from the same patient and, therefore, were considered as confirmed (CAA) (Supplemental Table 2 ). In addition, two cases utilizing the IGHV3-21 gene were observed to carry a confirmed serine deletion at IMGT/HCDR2 codon 59 (Supplemental Table 3 
Amino acid changes in subcloned IGHV-D-J sequences of subset #4 cases
The frequency of AA changes among subcloned sequences was significantly higher among subset #4 cases than all other cases analyzed (Supplemental Tables 2-6, Supplemental Figure 3 ). Of note, however, several changes identified in sets of subcloned sequences from subset #4 cases were rather conservative in terms of amino acid physicochemical properties (Figure 4 ). Novel changes were often "stereotyped", in the sense that different cases could share recurrent AA changes amongst subcloned sequences: therefore, the "options" for certain positions were remarkably restricted (Figure 4) . A comprehensive list of AA changes in sets of subcloned sequences from IGHV4-34 rearrangements of subset #4 cases is given in Supplemental Table 4 .
A remarkable impact of ID was evident in the HCDR3 sequences of subset #4 cases, with eleven of the twenty HCDR3 codons showing CAA changes. Importantly, for several cases, the amino acid diversity observed intraclonally was found to reflect the overall heterogeneity observed at subset level. In particular, amino acids appearing in some subcloned sequences of one case represented the predominant residues at the same position in another case (Figure 4 ; Supplemental Table 4 ). For instance, the only permitted options among subcloned sequences at position 105 (following the IMGT numbering for the V domain) were A or V, with "intra-subset" variation also reflected at intraclonal level. An unprecedented high level of ID was observed in the HFR4 of subset #4 rearrangements, with three HFR4 positions (codons 120, 123 and 125) identified as ID "hotspots" (Supplemental Table 4 ).
Taking into account the high number of CMs and UCMs among subset #4 IGHV4-34 rearrangements, it is remarkable that certain critical positions of the VH domain were essentially left unaltered by the ID process. For instance, the W residue at codon 7 in the HFR1 of IGHV4-34 which plays a critical role in the recognition of the I/i NAL epitope 47 , was preserved in 322/326 subcloned sequences from thirteen evaluated subset #4 cases. A similar case of sequence preservation was also observed in HCDR1. As previously shown by our group 18 , two glycine (G) residues at codons 28 and 36 of the HCDR1 of subset #4 cases were very frequently targeted for "subsetbiased" substitution by acidic residues (aspartate, D, or glutamate, E). This hallmark of SHM activity for subset #4 cases was not affected by ongoing mutational activity, as all observed mutations at codon 28 involved only G-D or G-E substitutions. In fact, the only CAA change at this position concerned the introduction of D or E residues and, in one case, substitution of D for E (Supplemental Table 4 ). Finally, the distinctive and "subset-biased" couplet of RR or KR dipeptides at the IGHD-IGHJ junction of subset #4 IGHV4-34 rearrangements [17] [18] was not targeted by SHM and the only sign of mutational activity was an unconfirmed R-K replacement (Figure 4 ). 
DISCUSSION
Molecular analysis of the BCR in CLL has revealed biases in IG gene repertoire suggesting a potential role for antigenic stimulation in CLL ontogeny [8] [9] 21 . This notion has been further supported by the discovery of subsets of CLL cases carrying stereotyped BCRs. [10] [11] [12] [13] [14] [15] [16] [17] [18] As we have recently shown, a recurrent theme in subsets carrying mutated stereotyped BCRs is the presence of stereotyped, "CLL-" and "subset-biased" mutation patterns, alluding to a very precise, functionally-driven response to a restricted set of antigenic stimuli. 18, 48 Therefore, it can be concluded that SHM studies help to better understand and delineate critical issues in the history and biology of clonal malignant CLL cells. That notwithstanding, several important issues remain unresolved, especially with regard to the location, duration and nature of the interactions between the selecting antigens and the CLL precursors as well as the differentiation status of the precursor cells themselves.
As previously shown for other B cell malignancies, the study of intraclonal diversification (ID) of the clonotypic IG genes may provide important information that helps to address the aforementioned issues. More specifically, in some entities, such as follicular lymphoma, sporadic Burkitt lymphoma, splenic marginal zone lymphoma and MALT lymphoma, the analysis of SHM reveals ID, indicating that the neoplastic cells further diversify their IG genes through ongoing mutational activity [22] [23] [24] [25] [26] [27] [28] , either through conventional SHM in germinal centers (GCs) or unconventional SHM outside GCs. On the contrary, molecular analyses of IG genes in multiple myeloma showed intraclonal homogeneity suggesting that the myeloma clone derived from a postgerminal center memory B cell. [29] [30] The studies devoted to clarifying the possible occurrence and hence implications of ID in CLL have reached conflicting results. [31] [32] [33] [34] [35] [36] [37] These discrepancies may be attributed, at least in part, to differences in the sensitivity of various methods employed for detection of mutations [31] [32] [33] [34] [35] [36] [37] , usage of low-fidelity Taq polymerase [31] [32] [33] [34] [35] [36] [37] , number of analyzed subcloned sequences 34 , sample size or case selection. For instance, most studies analyzed relatively few patients [31] [32] [33] 35, 37 or even a single case 36 . Furthermore, an underrepresentation of certain CLL subsets with distinctive SHM patterns, namely cases utilizing the IGHV3-21 and IGHV4-34 genes (especially in subsets #2 or #4), was observed throughout all previous studies. Finally, the lack of a standard criterion for ID evaluation may also lead to ambiguity among previously reported data.
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Taking into consideration the above discrepancies, we conducted the present largescale subcloning study following a strict methodological approach in order to readdress ID in CLL. Our study included 71 carefully selected CLL cases, thereby enabling us to explore the presence of ID not only at cohort level, but also in subgroups defined by BCR stereotypy, IGHV gene mutational status and heavy chain isotype. In addition, a high-fidelity polymerase was used for all analyses, thus minimizing the incidence of errors. Finally, a large number of subcloned sequences per case (median: 21; range: 14-35) were evaluated.
At cohort level, 28% (20/71) of cases carried sets of identical subcloned sequences.
An additional 32% (23/71) of cases were characterized by the presence of mutations in single subcloned sequences and, following the strict definitions adopted in this study, could not be formally assigned to the intraclonally diversified category. What is important to mention, however, is that almost 40% (28/71) of cases carried intraclonally diversified IGHV-IGHD-IGHJ genes with confirmed mutations (CM) among subclones. CMs were identified in cases assigned to all mutational categories, even in the "truly unmutated" category (i.e. 100% identity to the germline).
Altogether, our results strongly support the notion that the SHM mechanism remains operative in CLL and suggest that antigen stimulation may be a promoting factor not only in the development of CLL clones but also in their evolution. However, the fact that ID was generally insubstantial in leukemic clones with unmutated IGHV genes that usually follow more aggressive clinical courses may be considered as evidence that their expansion is antigen-independent or, more likely, that their unmutated status confers a clonal advantage by permitting very efficient stimulation by a variety of self antigens that would be compromised or even abrogated upon alteration of the original BCR structure.
The molecular characteristics of mutations occurring in the context of ID are compatible with the idea that the underlying causal mechanisms may generally obey the same rules as the canonical SHM. 46, 49 More specifically, transitions were more common than transversions, in keeping with previous reports. 46, 49 However, the observed distribution patterns of CMs/UCMs differed from those reported as typical for mutations introduced by canonical SHM, leading to R/S ratios not characteristic of selection by conventional, T-dependent antigens. 50 The breakdown of the group of cases exhibiting ID revealed a striking bias for usage of the IGHV4-34 gene, especially in stereotyped IGHV4-34/IGKV2-30 BCRs of subset #4.
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. It is also worth underscoring the fact that the vast majority of mutations introduced within the context of the ID process were identified in subcloned sequences of IGHV4-34 rearrangements from subset #4 cases. Based on the above,
one could reasonably argue that in discussing the molecular characteristics of ID in CLL we are essentially describing the operation of ongoing mutational activity in subset #4.
In keeping with our previous reports [17] [18] , subset #4 cases included in the present study had a young median age at diagnosis (51 years, range: 37-69) and were diagnosed in early clinical stages; they were uniformly CD38-negative and IgGswitched; finally, 5/11 cases with available data carried del(13q) as the sole cytogenetic abnormality (Supplemental Table 7 ) . As recently shown by our group, 18 at a molecular level the distinctive features of this subset extend to SHM patterns in the clonotypic IG genes, including: (i) "non-canonical" distribution of R mutations, with low R/S mutation ratios in HCDRs (especially HCDR2); (ii) complete lack of mutations, leading to preservation of the germline conformation, at the IGHV4-34-specific motif which mediates superantigenic-like interactions with self-and exogenous elements; 47 (iii) recurrent, "stereotyped" hypermutations. 18 On these grounds, we proposed that the SHM characteristics in subset #4 are indicative of a particular mode of interaction with and selection by distinct (super)antigenic elements. 18 The results reported here reveal that the "subset-biased" impact of SHM extends to very distinctive patterns of ID. In particular, certain residues of the stereotyped IGHV4-34 rearrangements of subset #4 cases were identified as "hotspots" for ID;
these "hotspots" were scattered throughout the V domain, including, somewhat unexpectedly, HFR4. Interestingly, the observed amino acid changes at these "hotspots" were generally restricted ("stereotyped") and, with a few notable exceptions, conservative. This suggests that the permissible "options" at these positions are also restricted, perhaps by strong functional constraints for preservation of critical physicochemical properties. , we have previously postulated that the progenitors of CLL cases assigned to subset #4 may have originated as cells with reactivity against DNA or apoptotic bodies [17] [18] . Along these lines, it is worth mentioning that the single mutation observed at this dipeptide among
For personal use only. on . by guest www.bloodjournal.org From 15 326 subcloned sequences from subset #4 rearrangements concerned a substitution of K for R. This cannot be attributed to an overall lack of ID within HCDR3, given that other HCDR3 positions were frequently targeted for CMs or UCMs.
Interestingly, this single K-to-R mutation, though "unconfirmed", following the definitions adopted in our study, was "non-random": a simple inspection of the aligned subcloned sequences justifies considering this mutation as "confirmed by another case". Based on the findings reported in Results and also depicted graphically in Figure 3 , the same argument may hold true for several other mutations detected in single subcloned sequences. Therefore, although the practice of subdividing mutations into CM or UCM categories could be considered as a "safeguard" for reliability, finding mutations "unconfirmed at case level" which are "confirmed at subset level" raises the intriguing possibility that at least some UCMs should perhaps be counted as signs of true ID.
The strikingly different impact of ID in subset #4 cases vs. all other cases analyzed in this study could be thought to reflect an inherent mutability of the IGHV4-34 gene, or, alternatively, their mutated status or IgG-switched phenotype. However, on the evidence presented here, we argue that these findings cannot be attributed to In conclusion, our study convincingly demonstrates that the SHM mechanism may continuously operate in certain subsets of patients with CLL, especially patients expressing stereotyped IGHV4-34 rearrangements typical of subset #4. However, it is still difficult to reach definitive conclusions with regard to the duration of exposure to and stimulation by antigen as well as the functional impact of antigen on CLL evolution. That notwithstanding, the results reported here suggest a role for persistent antigenic stimulation rather than clonal expansion promoted by nonspecific stimuli, at least for subsets of CLL cases. L-AS and EK performed research, analyzed data, and wrote the paper. AH and ND performed research. AA provided samples and associated data. AT supervised research. RR and KS designed and supervised the research and wrote the paper.
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